| 词条 | Zymeworks |
| 释义 |
| name = Zymeworks Inc. | logo = Zymeworks Logo.svg | logo_size = 200px | type = Public | traded_as = {{TSX|ZYME}} | genre = | fate = | predecessor = | successor = | foundation = 2003 | founder = | defunct = | location_city = Vancouver, British Columbia | location_country = Canada | location = | area_served = | key_people = Ali Tehrani Donald L. Drakeman | industry = Biotechnology | products = Pharmaceuticals | production = | services = | revenue = | operating_income = | net_income = | aum = | assets = | equity = | owner = | parent = | num_employees = 155 (45 PhDs) | divisions = | subsid = | homepage = {{URL|http://www.zymeworks.com/}} | footnotes = | intl = }} Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure.[1][2][3] In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year.[4] In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade.[5] By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange. AzymetricThis is an IgG1-based heterodimeric antibody scaffold that consists of two different heavy chains engineered to exclusively assemble into a single molecule, allowing bi-specific binding to two different antigens or drug targets. The Azymetric™ scaffold is engineered by making amino acid changes in the CH3 region of the constant Fc domain of the IgG1.[6][7] This scaffold can also be engineered with tailored effector function and optimized serum half-life. Bi-specific antibody therapeutics potentially allow drug-makers to combine two existing drugs used as a cocktail into one potent therapeutic. Awards and recognition
References1. ^{{cite web | date=April 12, 2012 | url=http://zymeworks.com/about/index.html | title=About Zymeworks | accessdate=2012-04-12}} {{Canada-company-stub}}2. ^{{cite journal|last=Holmes|first=David|title=Buy Buy Bispecific Antibodies|journal=Nature Reviews Drug Discovery|year=2011|volume=10|pages=798|doi=10.1038/nrd3581|pmid=22037028}} 3. ^{{cite journal|last=DePalma|first=Angelo|title=Improving Classic Antibody Engineering: Diverse Methodologies and Fresh Insights Turn a Good Technique into an Even Better One|journal=Genetic Engineering and Biotechnology News|year=2011|volume=31|issue=36}} 4. ^{{cite web | url= http://www.hottopics.ht/stories/lists/10-healthtech-companies-raised-capital-2014 | title=The 10 healthtech companies that raised the most capital in 2014 | publisher=Hot Topics | date=January 2015 | accessdate=14 January 2015}} 5. ^{{Cite news|url=https://www.theglobeandmail.com/technology/zymeworks-ipo-bears-good-tidings-for-canadian-biotechnology/article35198952/|title=Zymeworks IPO bears good tidings for Canadian biotechnology|last=|first=|date=2017-06-04|work=The Globe and Mail|access-date=2018-02-20|archive-url=|archive-date=|dead-url=}} 6. ^{{cite web | date=April 19, 2012 | url=http://zymeworks.com/programs/azymetric.html | title=Azymetric | accessdate=2012-04-19}} 7. ^{{Cite journal|doi=10.4161/mabs.25632|pmid = 23924797|pmc = 3851217|title = Improving biophysical properties of a bispecific antibody scaffold to aid developability|journal = mAbs|volume = 5|issue = 5|pages = 646–654|year = 2014|last1 = von Kreudenstein|first1 = Thomas Spreter|last2 = Escobar-Carbrera|first2 = Eric|last3 = Lario|first3 = Paula I.|last4 = d'Angelo|first4 = Igor|last5 = Brault|first5 = Karine|last6 = Kelly|first6 = John F.|last7 = Durocher|first7 = Yves|last8 = Baardsnes|first8 = Jason|last9 = Woods|first9 = R. Jeremy|last10 = Xie|first10 = Michael Hongwei|last11 = Girod|first11 = Pierre-Alain|last12 = Suits|first12 = Michael D. L.|last13 = Boulanger|first13 = Martin J.|last14 = Poon|first14 = David K. Y.|last15 = Ng|first15 = Gordon Y.|last16 = Dixit|first16 = Surjit B.}} 8. ^) "http://lifesciencesbc.ca/announcements/2018-lifesciences-bc-annual-award-winners-announced/". Retrieved 2018-07-18. 9. ^) "https://www.zymeworks.com/news/zymeworks-receives-lifesciences-bc-life-sciences-company-year-award". Retrieved 2018-07-18. 10. ^"BIOTECanada :: Gold Leaf Awards". Retrieved 2015-09-17. 11. ^(April 4, 2011). "Congratulations to Zymeworks, #12 in 2011's Most Innovative Companies in B.C.". Retrieved 2012-04-12. 12. ^(March 1, 2011) "2011 Ready to Rocket Life Science Presentation" Retrieved 2012-04-12. 13. ^"2009 BIOTECanada Annual Report". Retrieved 2012-04-12. 5 : Biotechnology companies of Canada|Companies based in Vancouver|Pharmaceutical companies established in 2003|Pharmaceutical companies of Canada|Companies listed on the Toronto Stock Exchange |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。